Ovesterin
Estriol Vaginal Cream for Postmenopausal Vaginal Atrophy
Quick Facts About Ovesterin
Key Takeaways
- Ovesterin contains estriol, a naturally occurring oestrogen that acts locally on vaginal tissue with very low systemic absorption.
- It is used to treat vaginal dryness, irritation, and atrophy caused by declining oestrogen levels after menopause.
- Treatment starts with once-daily application for 2–3 weeks, then reduces to twice weekly for maintenance.
- Because systemic absorption is minimal, the risks associated with systemic hormone replacement therapy (HRT) are significantly lower.
- Do not use Ovesterin if you have known or suspected breast cancer, undiagnosed vaginal bleeding, active venous thromboembolism, or severe liver disease.
What Is Ovesterin and What Is It Used For?
Quick Answer: Ovesterin is a vaginal cream containing estriol, a natural oestrogen, used to treat vaginal dryness, irritation, and discomfort (vaginal atrophy) caused by oestrogen deficiency after menopause. It works locally with minimal systemic absorption.
Ovesterin belongs to a group of medicines called hormone replacement therapy (HRT) preparations, specifically designed for vaginal use. It contains the female sex hormone estriol, which is classified as an oestrogen. Unlike estradiol or conjugated equine oestrogens used in systemic HRT, estriol is a short-acting oestrogen with a weak and transient binding to oestrogen receptors, which contributes to its favourable safety profile when applied locally.
After menopause, the ovaries significantly reduce their production of oestrogens. This hormonal decline leads to changes in the vaginal and urogenital tissues, a condition known medically as vaginal atrophy (atrophic vaginitis) or, more comprehensively, genitourinary syndrome of menopause (GSM). The vaginal mucosa becomes thinner, drier, and less elastic, and the normal acidic vaginal environment is disrupted. This can cause symptoms including vaginal dryness, burning, itching, painful intercourse (dyspareunia), and increased susceptibility to urinary tract infections.
Ovesterin works by delivering estriol directly to the vaginal mucosa, where it stimulates the proliferation and maturation of epithelial cells, increases glycogen content, and helps restore the normal Lactobacillus-dominated vaginal flora. This process reverses the atrophic changes and restores vaginal health, improving lubrication, elasticity, and resistance to both mechanical stress and infection.
According to the International Menopause Society (IMS) and the European Menopause and Andropause Society (EMAS), local vaginal oestrogen therapy is the first-line treatment for GSM when vaginal symptoms are the primary concern. The North American Menopause Society (NAMS) consensus statement similarly recommends low-dose vaginal oestrogen as the preferred approach for isolated vulvovaginal symptoms. GSM affects up to 50–70% of postmenopausal women, yet it remains underdiagnosed and undertreated. Unlike vasomotor symptoms (hot flushes), which tend to improve over time, GSM typically worsens without treatment.
How Estriol Works
Estriol (E3) is one of the three naturally occurring oestrogens in the human body, alongside estradiol (E2) and estrone (E1). It is the weakest of the three and has a short duration of action at the oestrogen receptor. When applied vaginally, estriol is rapidly absorbed by the local tissue, producing a therapeutic effect on the vaginal mucosa without significant systemic oestrogenic stimulation. Peak plasma levels are reached within 1–2 hours and return to baseline within 4–8 hours, meaning the duration of receptor activation is brief.
This pharmacokinetic profile is clinically important: because estriol does not sustain oestrogen receptor activation, it does not significantly stimulate the endometrium at recommended vaginal doses, and the addition of a progestogen is not required. This distinguishes it from systemic oestrogen preparations, where progestogen is necessary to protect against endometrial hyperplasia in women with an intact uterus.
What Should You Know Before Using Ovesterin?
Quick Answer: Do not use Ovesterin if you have breast cancer, oestrogen-dependent cancers, undiagnosed vaginal bleeding, untreated endometrial hyperplasia, active blood clots, severe liver disease, or porphyria. A medical consultation is recommended before starting treatment, especially for first-time diagnosis of oestrogen deficiency.
Before starting Ovesterin, it is important to consider your medical history and discuss any concerns with your healthcare provider. Although Ovesterin acts locally with very low systemic absorption, certain conditions require caution or contraindicate its use entirely. Your doctor may ask about your personal and family medical history and may perform a general and gynaecological examination, including breast examination, before initiating treatment.
Once treatment has been started, regular medical check-ups are recommended at least once per year. At these check-ups, you and your doctor should discuss the benefits and risks of continuing treatment. You should also perform regular breast self-examinations and attend mammography screening when invited.
Contraindications
- You are allergic to estriol or any of the other ingredients in the cream
- You have or have ever had breast cancer, or it is suspected
- You have or have ever had an oestrogen-dependent cancer, such as endometrial cancer, or it is suspected
- You have unexplained vaginal bleeding that has not been investigated by a doctor
- You have untreated endometrial hyperplasia (excessive thickening of the uterine lining)
- You have or have recently had a venous thromboembolism (blood clot in the legs or lungs)
- You have a known thrombophilic disorder (protein C, protein S, or antithrombin deficiency)
- You have or have recently had an arterial thromboembolic disease (heart attack, stroke, angina)
- You have active liver disease with abnormal liver function tests
- You have porphyria, a rare inherited blood disorder
If any of the above conditions develop for the first time while using Ovesterin, you should stop using the cream immediately and contact your healthcare provider without delay.
Warnings and Precautions
Ovesterin vaginal cream should not be combined with systemic oestrogen preparations (such as tablets or patches), as the safety of such combinations has not been studied. Talk to your doctor before starting treatment if you have or have ever had any of the following conditions, as they may recur or worsen during treatment:
- Uterine fibroids (benign growths in the uterus)
- Endometriosis or a history of endometrial hyperplasia
- Increased risk of blood clots (see section on venous thromboembolism)
- Increased risk of oestrogen-dependent cancers (e.g., close relatives with breast cancer)
- High blood pressure
- Liver disease (e.g., benign liver tumour)
- Diabetes
- Gallstones
- Migraine or severe headaches
- Systemic lupus erythematosus (SLE)
- Epilepsy
- Asthma
- Otosclerosis (bone hardening in the middle ear causing hearing loss)
- Fluid retention due to heart or kidney disease
- Hereditary or acquired angioedema
- Yellowing of the skin or whites of the eyes (jaundice) – possible sign of liver disease
- Swelling of the face, tongue, or throat with difficulty swallowing or breathing (angioedema)
- A sudden significant increase in blood pressure (headache, fatigue, dizziness)
- New migraine-like headache for the first time
- Signs of a blood clot: painful swelling and redness in the leg, sudden chest pain, or difficulty breathing
- Pregnancy
Hormone Replacement Therapy and Cancer Risks
The following risks apply primarily to systemic HRT preparations that circulate in the bloodstream. Ovesterin vaginal cream is used locally, and systemic absorption is very low. The conditions described below are unlikely to worsen or recur during treatment with Ovesterin vaginal cream, but you should consult your doctor if you have concerns.
Endometrial cancer: Long-term use of systemic oestrogen-only HRT tablets can increase the risk of endometrial cancer. It is unclear whether there is a similar risk with Ovesterin when used repeatedly or for prolonged periods (over one year). However, systemic absorption has been shown to be very low, and the addition of a progestogen is not required. To prevent overstimulation of the endometrium, the maximum dose of one application (0.5 mg) per day should not be exceeded, and the maximum daily dose should not be used for longer than 4 weeks.
Breast cancer: Evidence suggests that Ovesterin vaginal cream does not increase the risk of breast cancer in women without a history of the disease. It is not known whether Ovesterin can be safely used by women who have previously had breast cancer. Check your breasts regularly and contact your doctor if you notice any changes such as dimpling, changes to the nipple, or lumps.
Ovarian cancer: Ovarian cancer is rare. Use of systemic oestrogen-only HRT has been associated with a slightly increased risk. Among women aged 50–54 not using HRT, about 2 in 2,000 will be diagnosed with ovarian cancer over a 5-year period. Among women who have used HRT for 5 years, approximately 3 in 2,000 will be diagnosed (about 1 extra case).
Blood Clots (Venous Thromboembolism)
The risk of venous blood clots is 1.3–3 times higher in women taking systemic HRT compared with non-users. It is not known whether Ovesterin carries the same risk, given its very low systemic absorption. Blood clots can be serious: a clot in the lungs can cause chest pain, breathlessness, collapse, or death.
You may be at higher risk if: you are immobilised for a long period due to surgery, injury, or illness; you are severely overweight (BMI over 30); you have a blood clotting disorder; a close relative has had blood clots; you have SLE; or you have cancer. If you need surgery, inform your surgeon that you are using Ovesterin, as you may need to stop treatment 4–6 weeks before the procedure.
Pregnancy and Breastfeeding
Ovesterin is intended for postmenopausal women. If you become pregnant, stop using Ovesterin and contact your doctor immediately. There is insufficient data on the use of estriol during pregnancy, and it should not be used in this context.
How Does Ovesterin Interact with Other Drugs?
Quick Answer: Because the estriol dose in Ovesterin is low and treatment is local, Ovesterin is not expected to significantly interact with other medicines. However, it should not be combined with systemic oestrogen preparations, and caution is advised with hepatitis C antiviral combinations containing ombitasvir/paritaprevir/ritonavir.
Drug interactions with Ovesterin vaginal cream are considered unlikely due to the low dose of estriol and its local application with minimal systemic absorption. Unlike oral oestrogen preparations, which undergo first-pass hepatic metabolism and can affect cytochrome P450 enzyme activity, vaginally applied estriol has negligible effects on hepatic drug metabolism. Nevertheless, there are a few important considerations.
Ovesterin should not be used concurrently with systemic oestrogen preparations (oral tablets, transdermal patches, or gels), as the safety and oestrogen levels achieved with such a combination have not been studied. Combining local and systemic oestrogens could theoretically lead to excessive oestrogenic stimulation.
If you have hepatitis C and are receiving a combination regimen of ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, inform your doctor. The combination of these medicines with certain oestrogen-containing products has been shown to cause elevated liver function tests (increase in the liver enzyme ALT). The risk of this occurring with Ovesterin is currently unknown, but caution is warranted.
| Interacting Drug | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Systemic oestrogen preparations (oral, patch, gel) | Additive oestrogenic effect | Not studied – potentially significant | Do not combine |
| Ombitasvir/Paritaprevir/Ritonavir (± Dasabuvir) | Elevated liver enzymes (ALT) | Risk unknown with Ovesterin | Inform your doctor; monitor liver function |
| Vaginal antifungals (e.g., clotrimazole pessaries) | Potential reduced absorption of estriol | Low – theoretical | Separate application times if possible |
| Latex condoms and diaphragms | Cream base may weaken latex | Moderate – barrier method failure | Allow 12 hours between application and use of latex barrier |
Always inform your doctor or pharmacist about all medicines you are taking, including over-the-counter products, herbal remedies, and supplements. Although significant drug interactions are unlikely with vaginal estriol, a complete medication review can help identify any potential concerns.
What Is the Correct Dosage of Ovesterin?
Quick Answer: Start with one application (0.5 mg estriol) daily at bedtime for 2–3 weeks, then reduce to one application twice per week as maintenance. Use the provided applicator to insert the cream into the vagina.
Always use Ovesterin exactly as your doctor or pharmacist has directed. The standard dosing regimen consists of an initial phase to restore the vaginal mucosa, followed by a maintenance phase to sustain the therapeutic effect. If you are unsure about the dose or how to use the applicator, consult your healthcare provider.
Adults (Postmenopausal Women)
Initial Phase (First 2–3 Weeks, Maximum 4 Weeks)
Apply one dose (0.5 mg estriol) daily, preferably at bedtime. Fill the applicator to the marked line (one full applicator), insert deeply into the vagina while lying on your back, and slowly press the plunger to release the cream.
Maintenance Phase
After 2–3 weeks, when symptoms have improved, reduce to one dose twice per week (e.g., Monday and Thursday). Continue at this reduced frequency for as long as directed by your doctor.
Maximum Dose
Do not exceed one application (0.5 mg) per day. The maximum daily dose should not be used for longer than 4 consecutive weeks to prevent overstimulation of the endometrium.
How to Use the Applicator
- Remove the cap from the tube and use the pointed end of the cap to puncture the seal on the tube.
- Screw the applicator nozzle onto the tube opening.
- Squeeze the tube gently to fill the applicator to the marked line (until the plunger stops).
- Unscrew the applicator from the tube and replace the cap on the tube.
- Lie on your back. Insert the applicator deeply into the vagina and slowly push the plunger to release the cream.
- After use, clean the applicator by pulling it apart and washing both pieces in warm soapy water. Rinse thoroughly. Do not use detergents or boiling water.
Elderly Patients
No dose adjustment is required for elderly patients. The standard dosing regimen (initial daily use followed by twice-weekly maintenance) applies to all postmenopausal women regardless of age. However, regular medical reviews are important, particularly for women over 65, as the general risks associated with HRT may be slightly different in older women.
Missed Dose
If you forget to apply a dose, use it as soon as you remember. However, do not apply a double dose to compensate for a missed one. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule.
Overdose
The estriol dose in Ovesterin vaginal cream is low and the treatment is local; therefore, overdose is not expected to occur from vaginal use. If the cream is accidentally swallowed (for example, by a child), contact a doctor or poison control centre for advice. Symptoms of oral oestrogen overdose may include nausea, vomiting, and vaginal bleeding in females.
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Initial treatment | 0.5 mg (1 applicator) | Once daily at bedtime | 2–3 weeks (max 4 weeks) |
| Maintenance | 0.5 mg (1 applicator) | Twice weekly | As directed by doctor |
| Maximum daily dose | 0.5 mg (1 applicator) | Not more than once daily | Max 4 weeks at daily dose |
What Are the Side Effects of Ovesterin?
Quick Answer: Common side effects include local vaginal irritation, breast tenderness, vaginal bleeding, nausea, and fluid retention. Side effects are generally mild and transient, and may indicate the dose is too high. Serious systemic side effects are unlikely due to the very low absorption.
Like all medicines, Ovesterin can cause side effects, although not everybody gets them. The side effects of Ovesterin are generally mild and resolve on their own. They may also indicate that the dose is too high and should be discussed with your doctor. Contact your healthcare provider if you experience vaginal bleeding, as this may require further investigation.
The following systemic conditions are reported more frequently in women using systemic HRT that circulates in the bloodstream than in non-users. These risks apply to a lesser extent to vaginally applied oestrogen treatments such as Ovesterin:
- Ovarian cancer
- Venous thromboembolism (blood clots in legs or lungs)
- Stroke
- Probable memory loss if HRT is started after age 65
Reported Side Effects (Frequency Unknown)
- Breast tenderness or discomfort
- Vaginal bleeding or spotting
- Nausea
- Fluid retention (e.g., swollen ankles or feet)
- Local vaginal irritation at the application site
- Flu-like symptoms
Reported with Other HRT Products
- Gallbladder disease
- Skin discolouration (chloasma/melasma) – dark patches especially on face and neck
- Erythema nodosum – painful reddish-purple lumps on the skin
- Erythema multiforme – ring-shaped red or ulcerated skin lesions
Rare Systemic Risks (Very Low with Vaginal Use)
- Venous thromboembolism (deep vein thrombosis, pulmonary embolism)
- Stroke
- Endometrial hyperplasia or cancer (risk minimised by not exceeding recommended dose)
- Increased risk of ovarian cancer (slight increase with systemic oestrogen-only HRT)
If breakthrough bleeding or spotting occurs, this is usually not a cause for concern, but you should make an appointment with your doctor. It may indicate that the uterine lining has thickened. If you experience any side effects not listed here, or if any side effect becomes severe, contact your healthcare provider.
How Should You Store Ovesterin?
Quick Answer: Store below 25°C. Do not freeze. Keep out of sight and reach of children. Do not use after the expiry date printed on the packaging.
Proper storage of Ovesterin ensures the cream remains effective and safe throughout its shelf life. Follow these guidelines:
- Temperature: Store at or below 25°C (77°F). Do not freeze the cream, as this may alter its consistency and effectiveness.
- Children: Keep this medicine out of the sight and reach of children.
- Expiry date: Do not use Ovesterin after the expiry date shown on the carton. The expiry date refers to the last day of the stated month.
- After opening: Use the tube within the period recommended by the manufacturer. Replace the cap tightly after each use.
- Disposal: Do not dispose of medicines via wastewater or household waste. Return unused medicines to your pharmacy for proper disposal to help protect the environment.
What Does Ovesterin Contain?
Quick Answer: Each gram of Ovesterin vaginal cream contains 1 mg of estriol as the active ingredient. One full applicator delivers 0.5 mg of estriol. Inactive ingredients include cetyl palmitate, cetyl alcohol, stearyl alcohol, and other cream base excipients.
Understanding the full composition of Ovesterin is important, particularly if you have known allergies or sensitivities to certain excipients. The complete list of ingredients is as follows:
Active substance: Estriol 1 mg/g (equivalent to 0.5 mg per dose from one full applicator).
Other ingredients (excipients):
- Octyldodecanol
- Cetyl palmitate
- Glycerol
- Cetyl alcohol
- Stearyl alcohol
- Polysorbate 60
- Sorbitan stearate
- Lactic acid
- Chlorhexidine dihydrochloride (preservative)
- Sodium hydroxide
- Purified water
Packaging: Ovesterin vaginal cream is supplied in an aluminium tube containing 15 g of cream, packaged in a carton together with one applicator.
Marketing authorisation holder: Aspen Pharma Trading Limited, Dublin, Ireland.
Manufacturer: Aspen Bad Oldesloe GmbH, Bad Oldesloe, Germany.
What Should You Do Before Surgery?
Quick Answer: If you are scheduled for surgery, inform your surgeon that you are using Ovesterin. You may need to stop treatment 4–6 weeks before the operation to reduce the risk of blood clots. Ask your doctor when it is appropriate to resume treatment.
If you are going to have surgery, it is important to tell the operating surgeon that you are using Ovesterin vaginal cream. Although the systemic absorption of vaginal estriol is very low, your doctor may recommend discontinuing treatment 4–6 weeks before the procedure as a precautionary measure to minimise the risk of venous thromboembolism during the postoperative recovery period, when the risk of blood clots is inherently increased due to immobility.
This recommendation follows the general guidance for all HRT preparations. Ask your doctor when it is appropriate to resume using Ovesterin after the operation. The decision will depend on the type of surgery, the duration of immobilisation, and your individual risk factors for blood clots.
Frequently Asked Questions About Ovesterin
Ovesterin is a vaginal cream containing estriol, a natural oestrogen. It is used to treat vaginal dryness, irritation, itching, burning, and discomfort caused by declining oestrogen levels after menopause – a condition known as vaginal atrophy or genitourinary syndrome of menopause (GSM). By restoring the vaginal mucosa locally, Ovesterin improves lubrication, elasticity, and resistance to infections.
For the first 2–3 weeks (maximum 4 weeks), apply one dose daily at bedtime using the applicator provided. Fill the applicator to the marked line, insert it deeply into the vagina while lying on your back, and slowly press the plunger to release the cream. After symptoms improve, reduce to one dose twice per week. Clean the applicator with warm soapy water after each use.
Low-dose vaginal estriol, such as Ovesterin, is generally considered safe for long-term use due to its very low systemic absorption. International guidelines from the IMS, EMAS, and NAMS support the use of local vaginal oestrogen therapy for extended periods. However, the daily dose should not exceed one application (0.5 mg) and should not be used at the maximum daily dose for more than 4 weeks. Regular medical reviews are recommended for ongoing use.
Ovesterin is contraindicated in women with known or suspected breast cancer, or a history of breast cancer. Although systemic absorption from vaginal estriol is very low, the safety of Ovesterin in breast cancer survivors has not been established. Women with a history of breast cancer should discuss alternative non-hormonal treatments for vaginal atrophy with their oncologist or gynaecologist.
The prescription status of Ovesterin varies by country. In many European countries, low-dose vaginal estriol preparations are available over the counter (OTC). However, an initial medical consultation is recommended to confirm the diagnosis of vaginal atrophy and rule out other conditions. Oestrogen deficiency should first be confirmed by a healthcare professional before starting treatment.
No effects on the ability to drive or operate machinery have been observed with Ovesterin. The cream is applied vaginally with minimal systemic absorption, and there are no known cognitive or psychomotor side effects that would impair your ability to drive or operate machinery safely.
References
- European Medicines Agency (EMA). Estriol – Summary of Product Characteristics. EMA Product Information Database.
- The NAMS 2020 GSM Position Statement Advisory Panel. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations. Menopause. 2020;27(10):1061–1066.
- Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. 2016;(8):CD001500.
- The North American Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement. Menopause. 2022;29(7):767–794.
- Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on Women’s Midlife Health and Menopause Hormone Therapy. Climacteric. 2016;19(2):109–150.
- NICE Guideline NG23. Menopause: diagnosis and management. National Institute for Health and Care Excellence. Updated 2019.
- Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753–756.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023.
- Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509–522.
- European Menopause and Andropause Society (EMAS). EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas. 2019;123:35–41.
Editorial Team
This article was researched and written by the iMedic Medical Editorial Team, a multidisciplinary group of licensed healthcare professionals with expertise in gynaecology, clinical pharmacology, and women's health.
All medical content is reviewed by board-certified specialists following the GRADE evidence framework, WHO guidelines, EMA recommendations, and NICE guidelines. Evidence level: 1A.
iMedic maintains strict editorial independence with no pharmaceutical industry funding or advertising. All content is evidence-based and regularly updated to reflect current medical knowledge.